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Abstract 
We report on a 4-year progression-free survival of a 54-year-old female first diagnosed in 
December 2007 with advanced bilateral ovarian cancer FIGO IIIc, disseminated peritoneal 
carcinosis and malignant diaphragm invasion. Treatment started in January 2008 with 6 
cycles of Taxol 175 mg/m
2/carboplatin AUC 5 in 3-week intervals. Twenty-four hours 
following each chemotherapy session, fever-range long-duration whole-body hyperthermia 
(WBH) was performed at the temperature plateau of 40°C body core temperature for 6 h. 
Three months after completion of chemotherapy, 4 more long-duration WBH procedures 
were performed in monthly intervals. Importantly, long-duration WBH was paralleled with 
intradermal vaccination of autologous dendritic cells. No other treatment was given to the 
patient. Four years following the first diagnosis, the patient is still in complete remission with 
no evidence of disease. 
 
Background 
Ovarian cancer usually has a poor prognosis, even more so the advanced-stage 
ovarian cancer described in this case report, despite radical surgery and adjuvant 
chemotherapy. For women with advanced ovarian cancer, the prognosis largely 
depends on the extent of tumor mass reduction at the initial surgery. Complete 
resection confers significantly longer survival (median 5 years) than incomplete 
resection. Because of the benefit of cytoreductive surgery and the efficacy of platinum 
plus paclitaxel first-line chemotherapy, these procedures have been established as the 
standard treatments for advanced epithelial ovarian cancer. In spite of this, long-term  
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survival has not improved. In the present case, disseminated peritoneal carcinosis and 
metastatic spread to the kidney and diaphragm represented far-advanced disease with 
an expected overall 5-year median survival of <23% [1]. 
Case Presentation 
Staging at initial diagnosis in December 2007 was G3, pT3c, N0 (0/4), Mx, R2. N. ovarii bilateralis 
with disseminated peritoneal carcinosis, cystic douglas cavity tumor with adhesion to the rectum and 
sigma, renal capsule metastasis, diaphragm metastasis above the liver in form of metastasis plate and 
metastasis in the omentum majus. Postoperative histology revealed low-differentiated diffuse and 
nodular partially papillary and partially solid-serous papillary adenocarcinoma of both ovaries G3.  
Surgical resection with median lower and upper laparotomy was performed in December 2007, 
including bilateral extirpation of the uterus and adnexa with lymphadenectomy, omentum majus 
resection, excision of the mesorectum with descend-rectostomy in a double-stapling procedure, 
disseminated metastases in the peritoneum and metastatic resection of lesions adherent to the colon 
ascendens, the capsule of Glisson and the diaphragm. 
Clinically, the patient presented with a painful cystic tumor in the rectovaginal area and moderate 
inflammatory and high tumor markers with a Karnofsky score of 80%. 
Treatment 
Initially, the patient underwent debulking surgery in December 2007 as described above. Signed 
informed consent was obtained from the patient. Adjuvant locoregional hyperthermia with a 
radiofrequency of 13.56 MHz (OncothermEHY2000) was performed over 2 weeks three times a week 
before the initiation of chemotherapy. 
From January to May 2008, adjuvant chemotherapy treatment was started with 6 cycles of Taxol 
175 mg/m2/carboplatin AUC 5 in 3-week intervals. Twenty-four hours following each chemotherapy 
session, fever-range long-duration whole-body hyperthermia (WBH; Heckel HT2000, Heckel 
Medizintechnik, Esslingen, Germany) was performed at the temperature plateau of 40°C body core 
temperature for 6 h under intensive care monitoring standards and light neuroleptic analgesia. The 
rationale and methodology of long-duration WBH have been described elsewhere [2–4]. 
From July to October 2008, 3 months after completion of chemotherapy, 4 more long-duration 
WBH procedures were performed in monthly intervals. Importantly, again long-duration WBH was 
paralleled with intradermal vaccination of autologous primed dendritic cells (DC; LANEX-DC, Cabion 
Technologies, Ulm, Germany) [5, 6]. In brief, LANEX-DC (long antigen exposition DC) were produced 
according to the GMP guidelines as follows:  
Peripheral blood mononuclear cells (PBMC) were isolated from 250 ml of heparinized venous 
blood of the patient by density-gradient centrifugation. PBMC were seeded in 6-well plates and after  
2 h the non-adherent cells were removed. Adherent cells were cultured in RPMI 1640 supplemented 
with 10% of the patient serum and L-glutamine in the presence of rh-GM-CSF and rh-IL-4 for 7 days. 
Maturation of monocyte-derived DC was induced by adding rh-IL-1β, rh-TNF-α and rh-IL-6. After  
24 h, monocyte-derived DC were harvested. The cells were suspended in 1 ml of sterile saline solution 
containing 10% autologous serum and administered by intracutaneous injection in the abdominal 
cutis near the inguinal lymph nodes (500 μl of cell suspension on each side). Vaccination was 
administered subcutaneously at two locations near the groin lymph nodes. 
Outcome and Follow-Up 
Restaging by full laboratory analysis including TM CA125, CEA and CT of the abdomen was 
performed in 6-month intervals. The patient is now, 4 years following the initial diagnosis, free of any 
signs of cancer in lasting complete remission. The CT of the abdomen in May and October 2008 and 
June and December 2009 all showed no signs of cancer recurrence. The TM CA125, which could be 
taken as laboratory surrogate marker, was still in the normal range in November 2011. An analysis of 
circulating tumor cells from the blood (PCR detection of tumor-specific gene expression) in December 
2009 was negative (fig. 1).  
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Discussion 
To our knowledge, this is the first advanced epithelial ovarian cancer case treated 
with a combination of thermochemotherapy and DC and followed up for 4 years 
without any evidence of disease recurrence.  
There is a rising interest in the use of hyperthermia for the treatment of cancer [7]. 
Basically, locoregional and WBH techniques have to be differentiated. The first is 
becoming increasingly established in teaching university settings and is also widely 
used by many practices and clinics, mainly in Germany. The latter also has a long-
standing tradition and has been introduced mainly by Heckel and von Ardenne in 
Germany, and Robins in the USA. In the 80s and 90s of the last century, some studies 
investigated the effects, treatment efficacy and immunological findings of high-
temperature (41.8–42°C) WBH in different cancers. Most studies were conducted in 
small patient numbers and in combination with chemotherapy. The clinical response 
rates in most of these studies of high temperature yielded marginal clinical benefit 
regarding (prolonged) progression-free survival or overall survival time. On the other 
hand, more moderate, fever-like temperatures clearly have been associated with 
lowered cancer incidence and remission of cancer [8]. 
Therefore, the use of fever-range (39.5–40.0°C) prolonged WBH (4–6 h at 
temperature plateau) has been mainly researched since the 90s of the last century by 
Bull and co-workers at the Division of Oncology, University of Texas Medical School [9] 
and Repasky and co-workers at the Roswell Park Cancer Centre [10]. An impressing 
amount of preclinical and to a smaller amount also clinical publications strongly 
confirmed the induction of immunological mechanisms relevant in the complex 
network of anti-tumor processes induced by WBH; moreover, the use of WBH in 
combination with different chemotherapy regimens demonstrated clear advantages 
over the use of chemotherapy alone. Importantly, timing and dosing of the applied 
methods and substances played a crucial role, pointing to the necessity to develop 
metronomic therapies in the treatment of patients suffering from cancer. 
There is a smaller in vitro and a larger in vivo part investigating different dose and 
time schedules of the combination of fever-range long-duration WBH with 
chemotherapy. The basic mechanism of the chemotherapy anti-cancer effects is the 
modification of cellular DNA by forming chemotherapy DNA adducts, altering the 
structure and function of proteins that interact directly with the genome [11]. Earlier 
studies demonstrated that chemotherapy acts synergistically with heat in vitro and in 
vivo. 
Hyperthermic intraperitoneal chemotherapy is under continuous evaluation as a 
potential treatment for ovarian cancer. Our approach with thermochemotherapy may 
be a concurrent methodology. 
Implications 
The results of this case report clearly underline and call for the necessity of further 
research and the rapid transfer of these findings into well-designed clinical phase II/III 
trials. 
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Fig. 1. Development of tumor marker CA125. CHT = Chemotherapy; LD-WBH = long-duration WBH. 
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